ライフサイエンスコーパス: antihypertensive

1 p were able to achieve SPRINT levels without antihypertensives.

2 etics are among the most commonly prescribed antihypertensives.

3 tia (1 trial, low strength of evidence); and antihypertensives (4 trials), NSAIDs (1 trial), and stat

4 ding 3 that studied dementia medications, 16 antihypertensives, 4 diabetes medications, 2 nonsteroida

5 Although 260 patients (69.7%) were taking antihypertensives, 42.9% of all blood pressures recorded

6 rved effect does not appear to depend on the antihypertensive action of this agent.

7 luated four food-derived peptides with known antihypertensive activities for antimicrobial activity a

8 as to evaluate and compare antioxidative and antihypertensive activities of Longissimus dorsi muscle

9 Pig meat showed antioxidative and antihypertensive activities, heat treatment decreased th

10 t of hydrolysis on potential antioxidant and antihypertensive activities.

11 Some peptides with antihypertensive activity also show antimicrobial activi

12 /g), whilst LSF extracts exhibited potential antihypertensive activity due to their large gamma-amino

13 nship between structure and dual antioxidant/antihypertensive activity of lentil peptides opening new

14 exhibits immunomodulatory, antimicrobial and antihypertensive activity.

15 9), as well as alphas2-casein (189-197) have antihypertensive activity.

16 Treatment with an antihypertensive agent alone is often insufficient to co

17 mg dose remains the most commonly prescribed antihypertensive agent in the United States.

18 with SR-HTN and A-HTN who reported use of an antihypertensive agent, 94% were on at least one of the

19 n), an FDA-approved drug formerly used as an antihypertensive agent, is capable of markedly increasin

20 ical therapy (with antiplatelet, statin, and antihypertensive agents plus lifestyle modification), me

21 Antihypertensive agents provide protection in normotensi

22 bined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assi

23 farin (presumably for deep-vein thrombosis), antihypertensive agents, and a statin.

24 were on at least one of the major classes of antihypertensive agents, but only 44% were on >/=2 class

25 e >/=160 mm Hg despite taking at least three antihypertensive agents, including a diuretic).

26 unction score, need for vasopressors, use of antihypertensive agents, need for mechanical ventilation

27 ortic surgery, compared to patients on other antihypertensive agents.

28 promising natural source of antioxidants and antihypertensive agents.

29 apy, thrombocyte aggregation inhibitors, and antihypertensive and antidiabetic medication.

30 dings revealed that WMRP displayed excellent antihypertensive and antioxidant activities.

31 This peptide was synthesised, its antihypertensive and antioxidant activity were evaluated

32 hnicity, smoking, height, weight, and use of antihypertensive and lipid-lowering drugs.

33 ity, cardiovascular risk factors, and use of antihypertensive and lipid-lowering drugs.

34 of the model was performed in data from the Antihypertensive and Lipid-Lowering Treatment to Prevent

35 erformed a secondary analysis of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent

36 the use of the structure of renin to design antihypertensives and the structure of HIV protease in d

37 eal the lipid-lowering, insulin-sensitizing, antihypertensive, and anti-inflammatory properties of ci

38 ng biological activity, including those with antihypertensive, antimicrobial, immunomodulatory, opioi

39 c regression model that controlled for other antihypertensives, aspirin, steroids, nonsteroidal anti-

40 f desfluorinated side products of the potent antihypertensive beta-blocker nebivolol are reported.

41 hibited significantly higher antioxidant and antihypertensive capacities than fractions with higher m

42 Finally, their antioxidant and antihypertensive capacities were evaluated after in vitr

43 All hydrolysates showed antihypertensive capacity, obtaining IC50 values from 29

44 out pass rates, sensitivity varied from 30% (antihypertensive class) to 100% (coronary risk assessmen

45 ication was defined by the addition of a new antihypertensive class, and separately, titration by the

46 ification, antihypertensive intensification, antihypertensive class, carotid stenosis intervention, a

47 Median antihypertensive costs from Shanghai and Yunnan province

48 parked interest in developing new classes of antihypertensive diuretics targeting ROMK.

49 In adults with hypertension, how do various antihypertensive drug classes differ in their benefits a

50 stic sensitivity analyses explored ranges of antihypertensive drug effectiveness and costs, monitorin

51 tigational drug was compared with the common antihypertensive drug nifedipine, which has 4.5-fold sel

52 Hg) who were randomly assigned to an active (antihypertensive drug or more intensive regimen) or cont

53 Recommended low-salt diet and triple antihypertensive drug regimens that include a diuretic,

54 lood pressure, adding meaningful efficacy to antihypertensive drug regimens.

55 encing data to identify molecular markers of antihypertensive drug response.

56 noic acid and Idoxuridine and reduced by the antihypertensive drug Spironolactone.

57 mm Hg, [-9.47 to -0.79]) as their additional antihypertensive drug than in those receiving a thiazide

58 of a higher treatment rate and more intense antihypertensive drug treatment.

59 rdiovascular history, and lipid-lowering and antihypertensive drug treatments.

60 with randomisation stratified by additional antihypertensive drug use and insulin use at baseline, i

61 Advancing age, male sex, antihypertensive drug use, higher body mass index, previ

62 We aimed at evaluating racial differences in antihypertensive drug utilization patterns and blood pre

63 Spironolactone is an effective antihypertensive drug, especially for patients with resi

64 -dose HCTZ monotherapy is not an appropriate antihypertensive drug.

65 angiotensin system blocker and an additional antihypertensive drug.

66 VTDR, we also found novel associations with antihypertensive drugs (OR: 0.18; 95% CI: 0.06-0.61) and

67 on was found between use of other individual antihypertensive drugs and risk of psoriasis.

68 Novel factors associated with VTDR include antihypertensive drugs and statins.

69 fficult to control, often requiring multiple antihypertensive drugs and treatment of other risk facto

70 ent submitted to medical therapy was free of antihypertensive drugs at 12 months.

71 HTN trial, the prevalence of nonadherence to antihypertensive drugs at 6 months was high ( approximat

72 Lipid-lowering, anticoagulant, and antihypertensive drugs can prevent strokes, but may be u

73 ent parameters as indexes to predict how the antihypertensive drugs could influence muscle function.

74 ly and non-adjustment for lipid-lowering and antihypertensive drugs did not introduce major biases in

75 have an influence: 41.7% of patients taking antihypertensive drugs experienced a severe reaction com

76 nce of baseline comorbidities, and trials of antihypertensive drugs for indications other than hypert

77 The fixed-dose combination of any two antihypertensive drugs from different drug classes is ty

78 patients' age in regression analysis, taking antihypertensive drugs had no effect on symptom severity

79 iption of lipid-lowering, anticoagulant, and antihypertensive drugs is important to reduce the incide

80 stolic hypertension while taking two or more antihypertensive drugs or chronic kidney disease to medi

81 and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and p

82 ly and non-adjustment for lipid-lowering and antihypertensive drugs resulted in marginal changes in O

83 Taking antihypertensive drugs seemed to have an influence: 41.7

84 ribed when lipid-lowering, anticoagulant, or antihypertensive drugs were clinically indicated but wer

85 igible for lipid-lowering, anticoagulant, or antihypertensive drugs were not prescribed them prior to

86 Lipid-lowering therapy, antihypertensive drugs, and anticalcific therapy have be

87 hageal reflux disease drugs, diabetes drugs, antihypertensive drugs, hypnotic drugs approved for the

88 al outcomes) based on blood pressure, use of antihypertensive drugs, plasma potassium and aldosterone

89 rugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids, attention-deficit/hy

90 ion comprised withdrawal of antidiabetic and antihypertensive drugs, total diet replacement (825-853

91 s, and 25% (1,740/7,008) were not prescribed antihypertensive drugs.

92 icated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs.

93 sure >/=90 mmHg, and/or self-reported use of antihypertensive drugs.

94 lemented by the sequential addition of other antihypertensive drugs.

95 right after generic commercialization for 3 antihypertensive drugs.

96 The antioxidant activity, antihypertensive effect and prebiotic activity of Mailla

97 system contribute, at least in part, to the antihypertensive effect of DHI in SHR.

98 We assessed the long-term antihypertensive effects and safety.

99 od pressure and the tissue that mediates its antihypertensive effects are currently unknown.

100 Furthermore, antihypertensive effects in spontaneously hypertensive r

101 a stabilized alphaAnalogue, by mediating (1) antihypertensive effects, (2) attenuating cardiac remode

102 a known antioxidant that is thought to have antihypertensive effects, the mechanism whereby pomegran

103 antidiabetic, antioxidative, antiobesity and antihypertensive effects.

104 biases potentially contributing to apparent antihypertensive effects: (a) regression to the mean, (b

105 We used two of these antihypertensives (felodipine and nilvadipine) for admin

106 Individuals with hypertension who used antihypertensives had less decline during the 20 years t

107 ic >/= 130 mm Hg, diastolic >/= 85 mm Hg, or antihypertensives); HDL cholesterol < 40 mg/dL (men) or

108 similarities, we observed suboptimal use of antihypertensives in this cohort and racial differences

109 ion, cholesterol medication intensification, antihypertensive intensification, antihypertensive class

110 of physical activity, cognitive training, or antihypertensive interventions showed some evidence of e

111 hanges in the use of and adherence to common antihypertensive, lipid-lowering, and hypoglycemic medic

112 ein ratio; diabetes; body mass index; use of antihypertensive, lipid-lowering, or anticholinergic med

113 for PM2.5 mass, age, body mass index, use of antihypertensive medication (ACE inhibitors, non-ophthal

114 sociated with a higher probability of taking antihypertensive medication (p = 6.7 x 10(-8)).

115 ith hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AH

116 ith hypertension who are not recommended for antihypertensive medication according to the 2017 ACC/AH

117 The presence of structural abnormalities or antihypertensive medication also correlated statisticall

118 The use of antihypertensive medication and hypertension control has

119 ociation between initiating and intensifying antihypertensive medication and serious fall injuries in

120 proportion of individuals with resistance to antihypertensive medication and/or poor compliance or to

121 of participants with diabetes were receiving antihypertensive medication at recruitment and 1% were r

122 130 to 180 mm Hg depending on the number of antihypertensive medication classes being taken, and hig

123 ease, self-monitoring with self-titration of antihypertensive medication compared with usual care res

124 who fail to take their prescribed statin and antihypertensive medication experience a substantially i

125 Children on antihypertensive medication had impaired physical functi

126 n to lower blood pressure with >/=1 class of antihypertensive medication identified through a pill bo

127 njury was increased during the 15 days after antihypertensive medication initiation (odds ratio, 1.36

128 ilable on the short-term risk of falls after antihypertensive medication initiation and intensificati

129 Antihypertensive medication initiation and intensificati

130 Antihypertensive medication initiation was defined by a

131 Antihypertensive medication number and percentages on >/

132 eneficiaries initiated, added a new class of antihypertensive medication or titrated therapy within 1

133 Patients on antihypertensive medication seem to be the most vulnerab

134 everity, background hypertension prevalence, antihypertensive medication treatment, case fatality, in

135 art disease and stroke risk reduction due to antihypertensive medication treatment.

136 Antihypertensive medication use has been associated with

137 ssure of at least 90 mm Hg, or self-reported antihypertensive medication use in the previous 2 weeks.

138 of diabetes mellitus, history of stroke, and antihypertensive medication use increased at higher low-

139 Antihypertensive medication use was self-reported.

140 olic blood pressure, current smoking status, antihypertensive medication use, diabetes mellitus, hist

141 ressure, fasting glucose, total cholesterol, antihypertensive medication use, glomerular filtration r

142 rs, including age, body mass index, smoking, antihypertensive medication use, or C-reactive protein l

143 ies, body mass index, SBP, diastolic BP, and antihypertensive medication use.

144 body mass index, vascular risk factors, and antihypertensive medication use.

145 Analyses were stratified by antihypertensive medication use.

146 ased on average blood pressure >/=140/90 and antihypertensive medication use.

147 A pharmacometabolomics study of antihypertensive medication was conducted and data were

148 (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (9

149 (95% CI: 30.1% to 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (9

150 ic ethnicity and requirement for more than 1 antihypertensive medication were independently associate

151 Among participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg,

152 Among U.S. adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.

153 Among US adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.

154 d drug treatment: 86% used statins, 90% used antihypertensive medication, and 98% used antithrombotic

155 They also received more antihypertensive medication, and a greater proportion re

156 ed diagnosis of hypertension, current use of antihypertensive medication, and blood pressure of less

157 duration, smoking, systolic blood pressure, antihypertensive medication, and BMI.

158 d pressure (BP) thresholds for initiation of antihypertensive medication, and BP target goals.

159 he percentage of U.S. adults recommended for antihypertensive medication, and more intensive BP lower

160 the percentage of US adults recommended for antihypertensive medication, and more intensive BP lower

161 tension, implications of recommendations for antihypertensive medication, and prevalence of BP above

162 tension, implications of recommendations for antihypertensive medication, and prevalence of BP above

163 atment received an average of one additional antihypertensive medication, and the systolic blood pres

164 le score (age, sex, systolic blood pressure, antihypertensive medication, diabetes mellitus, cigarett

165 ent smoking, systolic blood pressure, use of antihypertensive medication, diabetes mellitus, serum po

166 ormed in 3935 subjects who were not using an antihypertensive medication, lipid-lowering drugs, or a

167 sradipine, a general LTCC antagonist used as antihypertensive medication, not only blocks the inducti

168 60.1-76.0) among those taking and not taking antihypertensive medication, respectively.

169 Among participants taking antihypertensive medication, the regression-derived thre

170 Among participants not taking antihypertensive medication, the regression-derived thre

171 overt cardiovascular disease, and no use of antihypertensive medication.

172 to ensure patient compliance with absence of antihypertensive medication.

173 intensive BP lowering for many adults taking antihypertensive medication.

174 intensive BP lowering for many adults taking antihypertensive medication.

175 133 mm Hg, respectively, among those taking antihypertensive medication.

176 c characteristics (age, sex, income); use of antihypertensive medication; smoking; tooth loss; dental

177 nfidence interval: 2.15-17), and about their antihypertensive medications (odds ratio: 6.48; 95% conf

178 95% CI, 0.959-0.977), number of preoperative antihypertensive medications (RYGB: OR, 0.104; 95% CI, 0

179 3362 sites, 8.1% (95% CI 7.2-9.1) stocked no antihypertensive medications and 33.8% (32.2-35.4) stock

180 oring was most effective in those with fewer antihypertensive medications and higher baseline sBP up

181 cal condition, thus discounting the value of antihypertensive medications and interfering with medica

182 for 4 medical exposures (oestrogen, statin, antihypertensive medications and non-steroidal anti-infl

183 e of comorbid conditions, and current use of antihypertensive medications and nonsteroidal anti-infla

184 patients (57.7%) were completely weaned-off antihypertensive medications and their use dropped from

185 ts with high blood pressure (BP) do not have antihypertensive medications appropriately intensified a

186 ility, cost, and prescription patterns of 62 antihypertensive medications at primary health-care site

187 130 to 180 mm Hg (depending on the number of antihypertensive medications being taken), and high card

188 To date, no specific antihypertensive medications have been shown to be more

189 t current patterns of access to, and use of, antihypertensive medications in Chinese primary health c

190 netics and pharmacodynamics of the different antihypertensive medications need to be carefully consid

191 dex included systolic BP, anemia, and use of antihypertensive medications other than angiotensin-conv

192 scular deficits in AD.SIGNIFICANCE STATEMENT Antihypertensive medications that target the renin angio

193 imely initiation and subsequent titration of antihypertensive medications to achieve individualised B

194 In a separate analysis, the use of antihypertensive medications was independently associate

195 registration LVEF less than 65%, and use of antihypertensive medications were associated with an inc

196 Reduction of >/=30% of the total number of antihypertensive medications while maintaining controlle

197 s reduction of >/=30% of the total number of antihypertensive medications while maintaining systolic

198 sociation of prior existing hypertension and antihypertensive medications with risk of incident psori

199 betes, 54% had hypertension (47% were taking antihypertensive medications), and 60% had hyperlipidemi

200 (or 85 to 105 mm Hg if the woman was taking antihypertensive medications), and a live fetus.

201 blood pressure >/=90 mm Hg, or initiation of antihypertensive medications).

202 is, 30.1% (30.0-30.2) were taking prescribed antihypertensive medications, and 7.2% (7.1-7.2) had ach

203 ibodies, discontinuation of antiplatelet and antihypertensive medications, and any increase of 1 trad

204 physical activity, systolic blood pressure, antihypertensive medications, diabetes mellitus, diabeti

205 s have an elevated risk of hypertension, and antihypertensive medications, especially beta-blockers,

206 e of aspirin, statins, active vitamin D, and antihypertensive medications, in favor of the interventi

207 k, education on hypertension, prescribing of antihypertensive medications, laboratory monitoring, and

208 ombination of at least three optimally dosed antihypertensive medications, one of which is a diuretic

209 will need to improve access to, and use of, antihypertensive medications, paying particular attentio

210 h pre- or stage 1 hypertension and not using antihypertensive medications, were randomized to either

211 d with higher blood pressure, such as use of antihypertensive medications--may reduce AD risk.

212 determine history of hypertension and use of antihypertensive medications.

213 ients exhibited poor adherence to prescribed antihypertensive medications.

214 biennially updated data on hypertension and antihypertensive medications.

215 lic BP, female sex, anemia, and use of other antihypertensive medications.

216 tients were drug-naive or discontinued their antihypertensive medications.

217 ervation on blood pressure in the absence of antihypertensive medications.

218 the availability, cost, and prescription of antihypertensive medications.

219 s and 85 patients (75.9%) were taking ocular antihypertensive medications.

220 ective in China, provided low-cost essential antihypertensive medicines programs can be implemented.

221 even after excluding individuals prescribed antihypertensive or lipid-lowering therapies.

222 om interventions such as magnesium sulphate, antihypertensives, or transportation to a higher level o

223 This work evaluates, the presence of native antihypertensive peptides in five soybean-based infant f

224 ufacture of a functional ingredient based on antihypertensive peptides was attempted.

225 nce it is a good source of antioxidative and antihypertensive peptides.

226 logies with other recognized antioxidant and antihypertensive peptides.

227 ly hypertensive rat model to investigate the antihypertensive properties of pomegranate extract.

228 domization, patients were receiving a stable antihypertensive regimen involving maximally tolerated d

229 alysis, higher hemoglobin concentration, and antihypertensive regimens without beta-blockers or renin

230 to TD from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) (50 whites) and from P

231 nrolled in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study and treated with

232 mpensatory processes in the kidney can limit antihypertensive responses to this class of drugs.

233 These studies: (a) identify an antihypertensive role for the kidney Cyp2c44 epoxygenase

234 ing of blood pressure with self-titration of antihypertensives (self-management) results in lower blo

235 t lipid electrophiles such as NO2-OA mediate antihypertensive signaling actions by inhibiting sEH and

236 as an ideal ingredient in the production of antihypertensive supplements.

237 s a member of a fold group that includes the antihypertensive target angiotensin converting enzyme.

238 -negative but nonwhite or Hispanic and using antihypertensives, the APO rate was 58.0% and fetal or n

239 ular behaviors can provide insight to inform antihypertensive therapeutics in individuals with varian

240 eeclampsia and to assess the action of other antihypertensive therapies on rcSO2.

241 ith statins and other lipid-lowering agents, antihypertensive therapies, and antihyperglycemic treatm

242 rovide a potential target for individualized antihypertensive therapies.

243 lyzed according to whether ACEI/ARB or other antihypertensive therapy (excluding diuretics) was admin

244 However, participants receiving antihypertensive therapy (with blood pressure controlled

245 d ACEI/ARB and 24,001 (61.1%) received other antihypertensive therapy at year 1 after transplantation

246 is the optimal target for BP lowering during antihypertensive therapy in adults?

247 aptured year-by-year adherence to statin and antihypertensive therapy in both study groups and estima

248 hypotension; the effectiveness of nocturnal antihypertensive therapy in patients with coexistent neu

249 Antihypertensive therapy reduces the risk of cardiovascu

250 derate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting

251 59) for those nonadherent both to statin and antihypertensive therapy, 1.82 (95% CI: 1.43 to 2.33) fo

252 those non-adherent to statin but adherent to antihypertensive therapy, and 1.30 (95% CI: 0.53 to 3.20

253 Aspirin, lipid-lowering or antihypertensive therapy, and interim revascularization

254 multivariable models adjusting for age, sex, antihypertensive therapy, body mass index, heart rate, t

255 terol, estimated glomerular filtration rate, antihypertensive therapy, diabetes mellitus, and smoking

256 te, free of coronary heart disease (CHD) and antihypertensive therapy, from the Chicago Heart Associa

257 hough black patients received more intensive antihypertensive therapy, Hispanics were undertreated.

258 sis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reduc

259 relative to those who adhered to statins and antihypertensive therapy, the odds ratio at the year of

260 ssociated with nonadherence to statin and/or antihypertensive therapy.

261 se these drugs in patients already receiving antihypertensive therapy.

262 atient was discharged with anticoagulant and antihypertensive therapy.

263 equired further intensification of discharge antihypertensive therapy.

264 those adherent to statin, but nonadherent to antihypertensive, therapy.

265 edictor for LVH among patients not receiving antihypertensive treatment (P = 0.025).

266 mm Hg [38.5], p<0.0001; for patients not on antihypertensive treatment 159.2 mm Hg [27.8] vs 193.4 m

267 lood pressure than standardized stepped-care antihypertensive treatment alone.

268 care antihypertensive treatment, or the same antihypertensive treatment alone.

269 levels, and the use of CVD risk for guiding antihypertensive treatment among subgroups including old

270 We assessed adherence to antihypertensive treatment at 6 months by drug screening

271 a JNC-8-specified indication for initiating antihypertensive treatment at baseline was associated wi

272 rvation added to a standardized stepped-care antihypertensive treatment for resistant hypertension at

273 in addition to blood pressure (BP) to guide antihypertensive treatment is an active area of research

274 olute CVD risk reduction that can occur when antihypertensive treatment is guided by CVD risk.

275 rospective observational study nested in the Antihypertensive Treatment of Acute Cerebral Hemorrhage

276 We report the influence of adherence to antihypertensive treatment on blood pressure control.

277 ients who received ACEI/ARB therapy or other antihypertensive treatment overall and in subpopulations

278 review potential challenges in implementing antihypertensive treatment recommendations that incorpor

279 l denervation plus standardized stepped-care antihypertensive treatment resulted in a greater decreas

280 y nonadherent patients (7/40 versus 4/45) to antihypertensive treatment were not different in the ren

281 x, systolic blood pressure, body mass index, antihypertensive treatment, and previous myocardial infa

282 terol level, systolic blood pressure, use of antihypertensive treatment, current cigarette smoking, d

283 l denervation plus standardized stepped-care antihypertensive treatment, or the same antihypertensive

284 For standardized stepped-care antihypertensive treatment, spironolactone 25 mg/d, biso

285 ing CVD risk in conjunction with BP to guide antihypertensive treatment, the broad distribution in CV

286 t capture information on smoking or lipid or antihypertensive treatment, we validated our findings in

287 observed primarily during the first year of antihypertensive treatment.

288 lic and 85 mm Hg or higher diastolic despite antihypertensive treatment.

289 ons of sympathetic deactivation as a mode of antihypertensive treatment.

290 .4 mg daily) or placebo, along with standard antihypertensive treatment.

291 bably in relation to the optimization of the antihypertensive treatment.

292 ing CVD risk in combination with BP to guide antihypertensive treatment.

293 ations in a prospective study from the China Antihypertensive Trial in Acute Ischemic Stroke.

294 (odds ratio [OR], 8.32 [CI, 3.59 to 19.26]), antihypertensive use (OR, 7.05 [CI, 3.05 to 16.31]), PGA

295 andomized controlled trials (RCTs) examining antihypertensive use in octogenarians.

296 SD 12), 15 patients (50%) were men, and mean antihypertensive use was 4.4 drugs (1.4).

297 iral load, CD4 lymphocyte count, statin use, antihypertensive use, and antiretroviral medication use

298 ular risk factors, including blood pressure, antihypertensive use, prevalent CMBs, and markers of cer

299 , labile international normalized ratio, and antihypertensive use.

300 Her medications include an antihypertensive, vitamin D, and calcium.